产品
编 号：F170265
分子式：C24H28O4
分子量：380.48
分子式：C24H28O4
分子量：380.48
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
结构图
CAS No: 146670-40-8
产品详情
生物活性：
SR11237 (BMS-649) is a potent retinoid X receptor (RXR)-selective agonist that is devoid of any RAR activity. SR11237 can cause RXR/RXR homodimers to form and transactivate a reporter gene containing a RXR-response element.
体内研究：
SR11237 (BMS-649) (25 mg/kg; i.p.; daily from post-natal days 5 to 15) causes irregular ossification and premature closure of the growth plate.Animal Model:Sprague-Dawley rats
Dosage:25 mg/kg
Administration:I.p.; daily from post-natal days 5 to 15
Result:Caused disturbed ossification and bone morphology in rats, including premature growth plate closure and infiltration of ossified tissue through the central epiphysis.
体外研究：
Using nuclear receptor co-transfection assays in COS-1 cells, that SR11237 is effective at transactivating a chloramphenicol acetyltransferase reporter gene through RXRs but not retinoic acid receptors.
SR11237 (BMS-649) is a potent retinoid X receptor (RXR)-selective agonist that is devoid of any RAR activity. SR11237 can cause RXR/RXR homodimers to form and transactivate a reporter gene containing a RXR-response element.
体内研究：
SR11237 (BMS-649) (25 mg/kg; i.p.; daily from post-natal days 5 to 15) causes irregular ossification and premature closure of the growth plate.Animal Model:Sprague-Dawley rats
Dosage:25 mg/kg
Administration:I.p.; daily from post-natal days 5 to 15
Result:Caused disturbed ossification and bone morphology in rats, including premature growth plate closure and infiltration of ossified tissue through the central epiphysis.
体外研究：
Using nuclear receptor co-transfection assays in COS-1 cells, that SR11237 is effective at transactivating a chloramphenicol acetyltransferase reporter gene through RXRs but not retinoic acid receptors.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备